title: [Level of evidence for therapeutic drug monitoring of teicoplatin].
abstract: Teicoplanin is a glycopeptid antibiotic used for treatment of serious infections caused by Gram+ bacteriae. The treatment scheme corresponds to an initial loading dose followed by maintenance dose. High interindividual pharmacokinetic variability and strong relation between high through concentrations, dose and clinical success, support the need of therapeutic drug monitoring using through concentrations. Achieving through concentrations ≥ 10-15 mg/L or ≥ 20-40 mg/L, regarding the measurement method and the infection severity, is recommended to increase clinical success rate. The level of proof of therapeutic drug monitoring is evaluated: "necessary".
authors.affiliation: Université de la Méditerranée, Marseille, France. audrey.boulamery@univmed.fr
authors.forename: Audrey
authors.initials: A
authors.lastname: Boulamery
authors.forename: Nicolas
authors.initials: N
authors.lastname: Venisse
authors.forename: Chantal
authors.initials: C
authors.lastname: Le Guellec
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring / Q000379:methods*; D019317:Evidence-Based Medicine; D006801:Humans; D007262:Infusions, Intravenous; D007674:Kidney Diseases / Q000150:complications / Q000378:metabolism; D017334:Teicoplanin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D017334:Teicoplanin